Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4145 Itanet national prospective database: A comprehensive analysis of epidemiology and clinical presentation of GEP-NEN in Italy

Introduction: Epidemiological data on GEP-NEN are heterogeneous, making interpretation difficult.

Conference:

Presenting Author:

Authors: Panzuto F, Partelli S, Campana D, Pusceddu S, Spada F,

Keywords: Neuroendocrine tumor, epidemiology, registry, management, database,

#3865 Prospective observational study on third-line treatments in neuroendocrine carcinoma – Data from the phase II SENECA trial

Introduction: Neuroendocrine Carcinoma (NEC) are very rare and characterized by a poor prognosis. Therapeutic opportunities for metastatic disease beyond the first line are very limited.

Conference:

Presenting Author: Liverani C

Authors: Bongiovanni A, Liverani C, Morbini S, Pusceddu S, Gelso F,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, third line, chemotherapy,

#3674 COVID-19 in patients with neuroendocrine neoplasms – Two-year results of a worldwide survey (The INTENSIVE study)

Introduction: Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021.

Conference:

Presenting Author: Gervaso L

Authors: Fazio N, Gervaso L, Halfdanarson T, Sonbol M, Pusceddu S,

Keywords: neuroendocrine, NEN, COVID-19, SARS-CoV-2,

#3671 GEP-NET and early progression after RLT – Application of a modified TGR to increase the accuracy of prediction

Introduction: Tumor Growth Rate (TGR) allows for early SSA and RLT response assessment in NET.

Conference:

Presenting Author: Scalorbi F

Authors: Scalorbi F, Calareso G, Garanzini E, Prinzi N, Pusceddu S,

Keywords: TGR, RLT, NET,

#3571 A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study)

Introduction: No standard 2nd line treatment has been validated in patients (pts) with metastatic or locally advanced, non-resectable, grade 3 gastroenteropancreatic (GEP) and lung NEC after first-line platinum therapy. Furthemore more accurate prognostic biomarkers are needed.

Conference:

Presenting Author: Bongiovanni A

Authors: Bongiovanni A, Foca F, Bergamo F, Leo S, Pusceddu S,

Keywords: neuroendocrine carcinoma, FOLFIRI, CAPTEM, second line, Phase 2, NEC, Temozolomide, Capecitabine,